HomeCompareGUERF vs BTI

GUERF vs BTI: Dividend Comparison 2026

GUERF yields 8.99% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $15.9K in total portfolio value
10 years
GUERF
GUERF
● Live price
8.99%
Share price
$22.25
Annual div
$2.00
5Y div CAGR
-40.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$5.21
Full GUERF calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — GUERF vs BTI

📍 BTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGUERFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GUERF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GUERF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GUERF
Annual income on $10K today (after 15% tax)
$764.04/yr
After 10yr DRIP, annual income (after tax)
$4.43/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, BTI beats the other by $2,377.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GUERF + BTI for your $10,000?

GUERF: 50%BTI: 50%
100% BTI50/50100% GUERF
Portfolio after 10yr
$29.9K
Annual income
$1,403.74/yr
Blended yield
4.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

GUERF
No analyst data
Altman Z
2.5
Piotroski
8/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GUERF buys
0
BTI buys
0
No recent congressional trades found for GUERF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGUERFBTI
Forward yield8.99%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-40.9%11.3%
Portfolio after 10y$21.9K$37.8K
Annual income after 10y$5.21$2,802.29
Total dividends collected$1.3K$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: GUERF vs BTI ($10,000, DRIP)

YearGUERF PortfolioGUERF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$11,231$531.24$11,301$601.08$70.00BTI
2$12,347$329.55$12,799$706.58$452.00BTI
3$13,411$200.10$14,527$832.38$1.1KBTI
4$14,470$120.05$16,527$982.75$2.1KBTI
5$15,555$71.54$18,846$1,162.95$3.3KBTI
6$16,686$42.48$21,545$1,379.49$4.9KBTI
7$17,879$25.17$24,694$1,640.41$6.8KBTI
8$19,146$14.90$28,378$1,955.69$9.2KBTI
9$20,495$8.81$32,702$2,337.79$12.2KBTI
10$21,934$5.21$37,794$2,802.29$15.9KBTI

GUERF vs BTI: Complete Analysis 2026

GUERFStock

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was founded in 1926 and is headquartered in Villepinte, France.

Full GUERF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this GUERF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GUERF vs SCHDGUERF vs JEPIGUERF vs OGUERF vs KOGUERF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.